Lindsey Shapiro, PhD, science writer —

In people with newly diagnosed multiple myeloma following a stem cell transplant, a triple-combination maintenance therapy — of Revlimid (lenalidomide), Kyprolis (carfilzomib) and dexamethasone — significantly extended the time to disease progression or death, by 49%, compared with Revlimid alone. That’s according to an interim analysis of…

A new investigational CAR T-cell therapy, called MCARH109, demonstrated an ability to shrink or eliminate the amount of cancer in patients with relapsed or refractory multiple myeloma, according to results from a dose-escalation Phase 1 trial. Safety findings showed the treatment at its highest dose was not safe for…

An upcoming clinical trial will evaluate the CAR T-cell therapy Abecma (idecabtagene vicleucel) in people newly diagnosed with multiple myeloma who had a suboptimal response to a standard stem cell transplant. Additional information about the KarMMa-9 trial, including its design and timing, will come at the earliest opportunity,…

More than 30 million people in 46 countries joined together to participate in Myeloma Action Month (MAM), a campaign in March to raise awareness of the rare blood cancer. The International Myeloma Foundation (IMF), which organized the month-long campaign, says the awareness efforts were a success and helped…

The International Myeloma Foundation (IMF) is opening its annual Myeloma Action Month (MAM) campaign with a variety of events and undertakings to raise disease awareness across the community and the public-at-large. “Action” is theme of this year’s monthlong event, held each March. “The focus for this year’s…